Metformin
The most commonly prescribed drug for type 2 diabetes in the world — with a well-understood metabolic mechanism and an intensively studied, but still unproven, potential to slow aging.
Number of studies
2
Safety
Moderate
Time to effects
Lowering of glycemia is usually visible within days to weeks of starting therapy and reaching the target dose.
Who it's for
Table of contents
TL;DR
The most commonly prescribed drug for type 2 diabetes in the world — with a well-understood metabolic mechanism and an intensively studied, but still unproven, potential to slow aging.
- →Effectively lowers glycemia in type 2 diabetes without the hypoglycemia risk typical of insulin
- →Well-understood, decades-long safety profile as a first-line drug
- →Low cost and wide availability worldwide
| Intervention type | Prescription drug (biguanide) |
|---|---|
| Level of evidence | Strong in type 2 diabetes; preliminary/hypothesis in the context of general anti-aging |
| Target group | People with type 2 diabetes or prediabetes, on a doctor's prescription |
| Time to effects | Lowering of glycemia — days to weeks |
| Preparation needed | Prescription, kidney function assessment before starting therapy |
| Status | Prescription drug — not a supplement, not for self-directed use |
Understand
Overview
Metformin is a drug used for decades as the standard first-line therapy for type 2 diabetes, derived from a guanidine compound naturally present in French lilac (Galega officinalis). It lowers blood glucose mainly by limiting glucose production in the liver, without the hypoglycemia risk typical of insulin or sulfonylureas.
Over the past decade, metformin has drawn additional interest beyond diabetology — cohort observations suggesting lower mortality and lower incidence of age-related diseases among diabetics taking metformin (even compared with non-diabetics) inspired the hypothesis that this drug might slow general aging processes, not just control glycemia. This inspired the design of the TAME trial (Targeting Aging with Metformin) in people without diabetes — however, no published, conclusive results from such a trial in healthy people exist yet.
Who can genuinely benefit from this, and who probably shouldn't use it? Metformin is a legal, well-studied prescription drug for people with type 2 diabetes or prediabetes — it is not a supplement for self-directed use 'for longevity' without a medical indication and prescription. The anti-aging hypothesis is scientifically interesting and actively researched, but at this stage it remains a hypothesis, not a proven anti-aging intervention in healthy people.
Mechanism of action
Metformin activates the enzyme AMPK (AMP-activated protein kinase) in liver cells, which inhibits gluconeogenesis — the process of producing new glucose from non-sugar substrates. This is the main mechanism by which it lowers blood glucose in people with type 2 diabetes, whose livers produce excess glucose regardless of the body's actual needs.
In parallel, metformin mildly inhibits complex I of the mitochondrial respiratory chain, which changes the cell's AMP-to-ATP ratio and further activates AMPK. AMPK is the cell's central 'energy sensor,' also involved in regulating autophagy and the response to metabolic stress — it's these broader, cell-wide effects of AMPK that underlie the hypothesis about metformin's potential effect on the rate of aging, independent of its effect on glycemia.
Activation of AMPK in the liver
Metformin activates the AMPK enzyme, the cell's central energy sensor.
Inhibition of gluconeogenesis
Active AMPK limits new glucose production by the liver, the main source of hyperglycemia in type 2 diabetes.
Mild inhibition of mitochondrial complex I
Changes the AMP-to-ATP ratio, further reinforcing AMPK activation.
Broader cellular effects of AMPK
AMPK also affects autophagy and the response to metabolic stress — the basis for the anti-aging hypothesis.
Evidence: strong — based on 2 studies in this database.
Benefits
Common myths
MythMetformin is a proven longevity drug that everyone should take.
FactData on its effect on the rate of aging in healthy people come mainly from cohort observations in diabetics, not from conclusive randomized trials in healthy people — the hypothesis is being actively studied (including through the TAME program) but is not confirmed.
MythMetformin and berberine are interchangeable with identical strength of effect.
FactBoth substances activate the same AMPK pathway, but the number, quality, and scale of metformin's clinical studies are incomparably larger than berberine's — these are not equivalent substitutes in terms of strength of evidence.
Forms & variants
Metformin comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Immediate-release metformin
The classic form, dosed 2–3 times daily.
Best for: Standard treatment of type 2 diabetes
Metformin XR (extended-release)
Dosed once daily, usually better tolerated by the stomach.
Best for: People with pronounced gastrointestinal discomfort on the standard form
Practice
Frequently asked questions
No — metformin is a drug dispensed only by prescription, requiring qualification and supervision by a doctor.
This is an actively studied hypothesis based on cohort observations in diabetics, but there is not yet conclusive evidence from randomized trials in healthy people.
Both activate the AMPK pathway and have a similar mechanism for lowering glycemia, but metformin has an incomparably larger and longer evidence base for clinical safety and efficacy.
Dosage & timing
Typical dose
Determined individually by a doctor, usually 500–2000 mg daily in divided doses, with meals
Form
Oral tablets, including extended-release (XR) forms that reduce gastrointestinal discomfort
Dosing and eligibility are determined solely by the prescribing doctor — metformin is a prescription drug.
Best times to take it
- Usually with meals, to reduce gastrointestinal discomfort
Safety
Side effects & contraindications
Possible side effects
Gastrointestinal discomfort (diarrhea, nausea) — the most common reason for discontinuing therapy
Risk of vitamin B12 deficiency with long-term use
Rare: lactic acidosis, mainly with kidney failure
Contraindications
Severe kidney failure
Severe liver or heart failure
Acute conditions that increase the risk of lactic acidosis (e.g., dehydration, sepsis)
Interactions
Iodinated contrast media used in imaging studies — may require temporarily stopping metformin
Excess alcohol increases the risk of lactic acidosis
Is it worth taking?
Who it's for
- People with type 2 diabetes or prediabetes, qualified by a doctor
- People interested in longevity medicine research — purely as a topic of observation, not a self-directed intervention
Not for
- Severe kidney failure
- Severe liver or heart failure
- Acute conditions that increase the risk of lactic acidosis (e.g., dehydration, sepsis)
Evidence
Worth knowing
Metformin is derived from a guanidine compound naturally present in French lilac (Galega officinalis), known in folk medicine since the Middle Ages.
The TAME trial (Targeting Aging with Metformin) is a planned clinical trial designed to assess metformin's effect on age-related diseases in people without diabetes.
Studies
Intensive glycemic control with metformin in overweight patients with type 2 diabetes reduced the risk of diabetes-related complications in one of the longest-running trials in diabetology.
UK Prospective Diabetes Study (UKPDS 34), The Lancet, 1998
Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34)
Strong evidenceUK Prospective Diabetes Study Group · The Lancet · 1998
A long-term trial showing that metformin reduces the risk of diabetes-related complications in overweight patients with type 2 diabetes.
View studyMetformin as a Tool to Target Aging
Early-stage evidenceBarzilai N, Crandall JP, Kritchevsky SB, Espeland MA · Cell Metabolism · 2016
A review paper presenting the scientific rationale for the TAME trial — the hypothesis that metformin might slow age-related diseases in people without diabetes.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.6Insulin Resistance
A state in which the body's cells respond more weakly to insulin, forcing the pancreas to produce ever-larger amounts of it — the most common, and largely reversible, precursor of type 2 diabetes.
4.7HbA1c (Glycated Hemoglobin)
A biomarker reflecting average blood glucose over the past 2–3 months — the gold standard for diagnosing and monitoring diabetes, far more stable than a single glucose measurement.
4.3Berberine
A plant alkaloid sometimes called 'nature's metformin' — studies show a meaningful effect on blood glucose, though it doesn't replace pharmacological treatment.
4.1NMN (Nicotinamide Mononucleotide)
An NAD+ precursor intensively studied in the context of cellular aging — human data are still early, despite huge market popularity.
4.9Strength Training
One of the single strongest predictors of healthy aging — it shapes muscle mass, bone density, and insulin sensitivity.
4.7Type 2 Diabetes
A chronic metabolic disease in which the body loses its ability to properly regulate blood glucose — and one of the few chronic diseases where a large randomized trial showed that lifestyle change alone can outperform a drug.
4.6Metabolic Syndrome
A cluster of five risk factors — from abdominal obesity to elevated triglycerides — that multiplies the risk of type 2 diabetes and cardiovascular disease, but is largely modifiable through lifestyle change.
4.4Statins
The best-researched class of LDL-cholesterol-lowering drugs, with one of the largest evidence bases in all of cardiology — yet still surrounded by numerous, largely unfounded fears.
Related articles
PoradnikiBerberine vs. Metformin: Does "Nature's Metformin" Really Measure Up?
"Nature's metformin" is one of the most repeated slogans in supplementation — and, surprisingly, one of the rare cases where a direct comparison with the drug actually exists. We check what that comparison really showed, how solid the 46-trial meta-analysis behind it is, and what popular headlines don't say about side effects.
August 22, 2026
PoradnikiTRT, Diabetes, and Insulin Resistance — Does Testosterone Affect Blood Sugar?
Low testosterone and insulin resistance go together far more often than chance would explain, and testosterone replacement therapy in men with hypogonadism and type 2 diabetes genuinely, though modestly, improves insulin sensitivity — but that's an addition to diabetes treatment, not a replacement for it.
August 15, 2026
PoradnikiWalking After Meals: How Much Does It Really Lower the Post-Meal Blood Sugar Spike?
"Be active" is advice so general it barely tells you when exactly to move. A randomized clinical trial in people with type 2 diabetes found something far more specific: a short walk right after a meal lowers the post-meal glucose spike more effectively than a generic recommendation to "meet your daily activity target" without specifying timing. What's more, the effect wasn't the same across all meals — after dinner specifically, walking cut the glucose spike by roughly 22%, considerably more than after other meals of the day. This suggests that for blood sugar control, what matters isn't just how much you move over 24 hours, but precisely when you do it. In this article we break down these findings step by step and explain exactly which population they've been shown in.
August 24, 2026
PoradnikiStatins and Type 2 Diabetes Risk: Do Cholesterol Drugs Raise Your Risk?
Statins are among the most widely prescribed drugs on earth, and their benefit in preventing heart attacks and strokes is one of the best-documented facts in all of cardiology. Less often discussed is another well-confirmed effect: statins genuinely increase the risk of newly diagnosed type 2 diabetes — not a fringe finding from a single study, but a result confirmed independently in the randomized JUPITER trial and in a meta-analysis of 13 trials covering more than 91,000 participants. The key, often-missed nuance is different from what the headline suggests: the increased risk falls almost entirely on people who already had diabetes risk factors, and the cardiovascular benefit of statins — even in that same group — is several times larger than the risk of causing one extra case of diabetes. This article explains why both facts are true at once, and why the authors of both studies, despite confirming the effect, unambiguously recommend continuing statin therapy.
August 25, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.